COMPARATIVE HEMATOLOGICAL PARAMETERS IN ACUTE VS. CHRONIC LEUKEMIA: A RETROSPECTIVE ANALYSIS IN A TERTIARY CARE HOSPITAL OF ROHILKHAND REGION

Main Article Content

Bir Parkash
Surabhi Pandey
Era Bhardwaj
Tanu Agrawal
Tappisana

Keywords

Leukaemia, Haematological parameters, Platelet count, Neutrophilia, Bone marrow suppression, Leucocytosis

Abstract

Leukaemia encompasses a heterogeneous group of haematological malignancies characterised by abnormal proliferation of white blood cells. Distinguishing between acute and chronic leukaemia using readily available laboratory parameters remains vital, particularly in resource-limited settings where advanced diagnostics may not be accessible. This study aimed to compare haematological parameters between patients diagnosed with acute leukaemia and those with chronic leukaemia, and to identify key laboratory indicators that could aid in differential diagnosis.  A retrospective, cross-sectional study was conducted on 100 patients diagnosed with leukaemia at a tertiary care hospital. Patients were categorised into acute and chronic groups based on clinical records. Haematological parameters, including total leukocyte count, red blood cell count, platelet count, differential leukocyte percentages, and erythrocyte sedimentation rate, were retrieved from hospital records. Statistical analysis was performed to compare the two groups, with significance determined using appropriate tests.  Patients with acute leukaemia exhibited significantly lower red blood cell and platelet counts, suggestive of bone marrow suppression. Chronic leukaemia cases demonstrated elevated total leukocyte counts and neutrophil predominance. No significant differences were observed in lymphocyte, monocyte, eosinophil, or basophil percentages. A significant age-related difference was also noted, with younger individuals more commonly presenting with acute leukaemia.  Basic haematological parameters provide important diagnostic clues in distinguishing between acute and chronic leukaemia. Their routine evaluation may enhance early clinical decision-making, though future multicentre studies incorporating cytogenetic and molecular markers are warranted.

Abstract 205 | PDF Downloads 27

References

1. Munir AH, Khan MI. Pattern of basic hematological parameters in acute and chronic leukemias. J Med Sci. 2019;27(2):125–9.
2. Ahmed AA, Khaleel KJ, Fadhel AA, et al. Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features. Bionatura. 2022;7(3):41.
3. Almuqrin AM, Alotaibi BA, Aldali JA, et al. Assessing the impact of COVID-19 on acute leukemia patients: a comparative analysis of hematological and biochemical parameters. BMC Infect Dis. 2024;24(1):576.
4. Khan MI. Acute myeloid leukemia: pattern of clinical and hematological parameters in a tertiary care centre. Int J Pathol. 2018;58–63.
5. Asghar MS, Khan NA, Haider Kazmi SJ, et al. Hematological parameters predicting severity and mortality in COVID-19 patients of Pakistan: a retrospective comparative analysis. J Community Hosp Intern Med Perspect. 2020;10(6):514–20.
6. Ding R, Wang Z, Lin Y, et al. Comparison of a new criterion for sepsis-induced coagulopathy and International Society on Thrombosis and Haemostasis disseminated intravascular coagulation score in critically ill patients with sepsis 3.0: a retrospective study. Blood Coagul Fibrinolysis. 2018;29(6):551–8.
7. Battipaglia G, Labopin M, Hamladji RM, et al. Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021;127(2):209–18.
8. Levy I, Lavi A, Zimran E, et al. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. Leuk Lymphoma. 2021;62(14):3384–93.
9. Ding X, Yu Y, Lu B, et al. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019. Clin Chem Lab Med. 2020;58(8):1365–71.
10. Mottal N, Issa N, Dumas PY, et al. Reduce mortality and morbidity in acute myeloid leukemia with hyperleukocytosis with early admission in intensive care unit: a retrospective analysis. J Hematol. 2020;9(4):109.
11. Shanbehzadeh M, Afrash MR, Mirani N, Kazemi-Arpanahi H. Comparing machine learning algorithms to predict 5-year survival in patients with chronic myeloid leukemia. BMC Med Inform Decis Mak. 2022;22(1):236.
12. Wang S, Song Y, Shi N, Yin D, et al. Characteristics, outcomes, and clinical indicators of bloodstream infections in neutropenic patients with hematological malignancies: a 7-year retrospective study. Infect Drug Resist. 2023;4471–87.
13. Clé DV, Atta EH, Dias DS, Lima CB, et al. Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study. Ann Hematol. 2018;97(11):2039–46.
14. Mandal P, Samaddar S, Chandra J, Parakh N, et al. Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study. Indian J Hematol Blood Transfus. 2020;36(3):498–504.
15. Orhan B, Özkalemkaş F, Özkocaman V, Gürbüz B, et al. The role of white blood cell count in perianal pathologies: a retrospective analysis of hematologic malignancies. Mediterr J Hematol Infect Dis. 2022;14(1):e2022051.
16. Gorin NC, Labopin M, Blaise D, de Groot M, et al. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: a retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Cancer. 2020;126(5):1004–15.
17. Castillo-Tokumori F, Talati C, Al Ali N, Sallman D, et al. Retrospective analysis of the clinical use and benefit of lenalidomide and thalidomide in myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020;20(12):e956–60.
18. Ferraro F, Gao F, Stockerl-Goldstein K, Westervelt P, et al. Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. Leuk Res. 2018;72:86–91.
19. Jin B, Zhang Y, Hou W, Cao F, et al. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide. J Cancer Res Clin Oncol. 2020;146(2):485–92.
20. Jin B, Zhang Y, Hou W, Cao F, et al. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide. J Cancer Res Clin Oncol. 2020;146(2):485–92.
21. Arbore DR, Galdean SM, Dima D, Rus I, et al. COVID-19 impact on chronic myeloid leukemia patients. J Pers Med. 2022;12(11):1886.
22. Khan M, Cox TM, Nassif M, Alzubaidi MA, et al. Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center. J Thromb Thrombolysis. 2018;45(3):377–85.